These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18490647)

  • 1. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
    Hirte HW; Hotte SJ
    J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
    J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
    Cortes J; Baselga J
    J Clin Oncol; 2009 Nov; 27(33):5492-4. PubMed ID: 19786653
    [No Abstract]   [Full Text] [Related]  

  • 4. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
    Moulder SL; Arteaga CL
    Clin Breast Cancer; 2003 Jun; 4(2):142-5. PubMed ID: 12864943
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in HER2-positive breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
    [No Abstract]   [Full Text] [Related]  

  • 6. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Arteaga CL
    J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
    Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
    Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
    Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular-targeted agents in breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):747-53. PubMed ID: 16770092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
    Normanno N; Campiglio M; Perrone F; De Luca A; Menard S
    Ann Oncol; 2005 Oct; 16(10):1709. PubMed ID: 16150806
    [No Abstract]   [Full Text] [Related]  

  • 14. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
    Bianchi GV; Duca M; Sica L; Mariani G
    Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
    Cameron D
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy of breast cancer with molecular targeting agents.
    Gasparini G; Longo R; Torino F; Morabito A
    Ann Oncol; 2005 May; 16 Suppl 4():iv28-36. PubMed ID: 15923426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
    Puglisi F; de Azambuja E; de Castro G; Demonty G
    J Clin Oncol; 2005 Sep; 23(27):6803-4; author reply 6804-5. PubMed ID: 16170195
    [No Abstract]   [Full Text] [Related]  

  • 18. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 20. Ten years of HER2-directed therapy: still questions after all these years.
    Krop IE; Winer EP
    Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.